[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100576970":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":31,"centralContacts":32,"locations":38,"responsibleParty":101,"collaborators":103,"id":108,"slug":109,"hasResults":110,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":110,"sex":116,"minAge":117,"maxAge":31,"enrollmentInfo":118,"targetDuration":31,"studyType":121,"phases":122,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":74,"whyStopped":31,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":139},{"fullName":5,"class":6},"Mount Sinai Hospital, Canada","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Paxlovid","EXPERIMENTAL","Paxlovid vs. placebo",[13],"Drug: Nirmatrelvir\u002Fritonavir",{"label":15,"type":10,"description":16,"interventionNames":17},"Veklury","Veklury vs. placebo",[18],"Drug: Remdesivir",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Nirmatrelvir\u002Fritonavir","Paxlovid PO BID for 5 days + standard of care",[9],[9],{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"Remdesivir","Veklury IV daily for 5 days + standard of care",[15],[15],null,[33],{"name":34,"role":35,"phone":36,"phoneExt":31,"email":37},"Dr. Kieran Quinn","CONTACT","416-843-8403","kieran.quinn@mail.utoronto.ca",[39,58,72,89],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Kingston Health Sciences Centre","NOT_YET_RECRUITING","Kingston","Ontario","K7L 2V7","Canada","CA",{"type":48,"coordinates":49},"Point",[50,51],-76.48098,44.22976,{"lat":51,"lon":50},[54],{"name":55,"role":35,"phone":56,"phoneExt":31,"email":57},"Dr. Siddhartha Srivastava","613-533-2780","srivastava.s@queensu.ca",{"facility":59,"status":41,"city":60,"state":43,"zip":61,"country":45,"countryCode":46,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Niagara Health System","St. Catharines","L2S 0A9",{"type":48,"coordinates":63},[64,65],-79.24267,43.17126,{"lat":65,"lon":64},[68],{"name":69,"role":35,"phone":70,"phoneExt":31,"email":71},"Dr. Jennifer Tsang","905-684-7271","jennifer.tsang@niagarahealth.on.ca",{"facility":73,"status":74,"city":75,"state":43,"zip":76,"country":45,"countryCode":46,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Mount Sinai Hospital, Sinai Health System","RECRUITING","Toronto","M5G 1X5",{"type":48,"coordinates":78},[79,80],-79.39864,43.70643,{"lat":80,"lon":79},[83,84,86],{"name":34,"role":35,"phone":36,"phoneExt":31,"email":37},{"name":34,"role":85,"phone":31,"phoneExt":31,"email":31},"PRINCIPAL_INVESTIGATOR",{"name":87,"role":88,"phone":31,"phoneExt":31,"email":31},"Dr. Mike Fralick","SUB_INVESTIGATOR",{"facility":90,"status":41,"city":75,"state":43,"zip":91,"country":45,"countryCode":46,"cosmosGeoPoint":92,"geoPoint":94,"contacts":95},"St. Joseph's Health Centre, Unity Health Toronto","M6R 1B5",{"type":48,"coordinates":93},[79,80],{"lat":80,"lon":79},[96,100],{"name":97,"role":35,"phone":98,"phoneExt":31,"email":99},"Dr. Travis Carpenter","416-530-6692","travis.carpenter@unityhealth.to",{"name":97,"role":85,"phone":31,"phoneExt":31,"email":31},{"type":102,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR",[104,106,107],{"name":105,"class":6},"Unity Health Toronto",{"name":40,"class":6},{"name":59,"class":6},"100576970","phase-4-antiviral-strategies-in-the-prevention-of-long-term-cardiovascular-outcomes-following-covid-19-the-paxlovidremdesivir-effectiveness-for-the-prevention-of-long-covid-clinical-trial-100576970",false,"NCT06792214","Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD\u002FRemdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial","Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD\u002FRemdesivir Effectiveness For the prEvention of loNg coviD (DEFEND) Clinical Trial","DEFEND","Inclusion Criteria:\n\n* ≥18 years old\n* Positive PCR test for SARS-CoV-2 within 5 days of admission to hospital\n* Normoxic (not receiving supplemental oxygen)\n* Able to provide informed written consent (or, if patient is unable, have substitute decision maker available)\n\nExclusion Criteria:\n\n* Absolute contraindications to Paxlovid or Veklury (any of the following): Severe allergy to Paxlovid or Veklury (e.g. anaphylaxis), co-administration with drugs highly dependent on CYP3A for clearance, co-administration with potent CYP3A inducers\n* Exposure to Paxlovid or Veklury within previous 14 days;\n* Receiving supplemental oxygen;\n* Known positive SARS-CoV-2 PCR or rapid antigen test 5-90 days prior to admission;\n* Limited life expectancy estimated to be ≤3 months;\n* Pregnant and breastfeeding women","ALL","18 Years",{"count":119,"type":120},118,"ESTIMATED","INTERVENTIONAL",[123],"PHASE4","The DEFEND trial will be the world's first clinical trial to study the effectiveness of Paxlovid or Veklury in the prevention of cardiovascular post-acute sequelae of SARS-CoV-2 among hospitalized adults. Additionally, this pilot study will inform the design and conduct of a future full-scale multi-centre trial by testing the feasibility and accuracy of this study design.",[126],"SARS CoV-2 Post-Acute Sequelae",[128,129],"SARS CoV-2","long covid","2025-01-23",{"date":132,"type":133},"2025-01-24","ACTUAL",{"date":135,"type":133},"2025-01-03",{"date":137,"type":120},"2027-01",{"name":5,"class":6},4]